Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, tolerability, and efficacy of a single intravenous infusion of SPK-3006 in adults with clinically moderate, late-onset Pompe disease receiving enzy...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Spark Therapeutics, Inc.
NCT07282847 · Pompe Disease (Late-onset), Pompe Disease Late-Onset, and more
NCT06121011 · Pompe Disease
NCT07136844 · Neuromuscular Diseases, Obesity (Disorder), and more
NCT01665326 · Pompe Disease
NCT06150820 · Pompe Disease (Late-onset)
Barrow Neurological Institute
Phoenix, Arizona
University of California Irvine Health
Orange, California
Emory University School of Medicine
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions